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Serous ovarian cancer (SOC) is a significant cause of morbidity and mortality in females with poor prognosis because of advanced
stage at presentation. Recently, neoadjuvant chemotherapy (NACT) is being used for management of advanced SOC, but role of
tissue biomarkers in prognostication following NACT is not well established. The study was conducted on advanced stage SOC
patients (𝑛 = 100) that were treated either conventionally (𝑛 = 50) or with NACT (𝑛 = 50), followed by surgery. In order
to evaluate the expression of tissue biomarkers (p53, MIB1, estrogen and progesterone receptors, Her-2/neu, E-cadherin, and
Bcl2), immunohistochemistry and semiquantitative scoring were done following morphological examination. Following NACT,
significant differences in tumor histomorphologywere observed as compared to the native neoplasms.MIB 1 was significantly lower
in cases treated with NACT and survival outcome was significantly better in cases with low MIB 1. ER expression was associated
with poor overall survival. No other marker displayed any significant difference in expression or correlation with survival between
the two groups. Immunophenotype of SOC does not differ significantly in samples from cases treated with NACT, compared to
upfront surgically treated cases. The proliferating capacity of the residual tumor cells is less, depicted by low mean MIB1 LI. MIB 1
and ER inversely correlate with survival.
1. Introduction
Ovarian cancer is the second most common gynecological
cancer worldwide and one of the leading causes of death
due to malignancies in females [1]. Incidence of ovarian
cancer in India is lower than the western countries and affects
postmenopausal females in their sixties [2, 3]. Almost 90% of
malignant ovarian tumors arise from the surface epithelium,
serous carcinoma being the commonest histological subtype
[4–7]. Clinical symptoms are nonspecific andmore than 50%
of the cases come to attention at an advanced stage with a
poor long-term outcome. Conventional treatment of serous
ovarian cancer (SOC) comprises surgical removal of tumor,
followed by Platinum/Taxane based chemotherapy [8]. Cur-
rently, “sandwich therapy,” that is, neoadjuvant chemotherapy
(NACT) with interval debulking surgery and postsurgery
chemotherapy (CT), is preferred for advanced stage disease
(stage IIIC or IV, of the FIGO staging system).The efficacy of
this treatment protocol is presently under evaluation [7–9].
A number of prognostic factors for SOCs have been
described. The most important ones are FIGO staging and
volume of the residual disease after initial cytoreductive
surgery [10]. Apart from these, tumor grade, histological
subtype, and expression of tissue biomarkers are described
in conventionally managed high grade SOC [11–15]. With the
growing use of NACT in management of SOCs, it is essential
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to explore the post-NACT expression of tissue biomarkers
and evaluate their utility in prediction of response to therapy
and prognosis. Utility of p53, ER, PR, and MIB 1 LI has been
reported for this group in one study [9]. The present study
evaluates these and other biomarkers like Bcl2, E-cadherin,
and Her-2/neu in post-NACT samples which has not been
evaluated earlier.
2. Materials and Methods
This study was a combined retrospective and prospective
study including cases from January 2001 to December 2010
seen in theDepartments ofMedical Oncology and Pathology,
AIIMS,NewDelhi.One hundred cases of SOCwere included:
fifty treated with 3 cycles of NACT followed by surgery and 3
cycles of CT (NACT group) and fifty patients who underwent
upfront surgery (US) followed by 6 cycles of CT (US-CT
group).
Formalin-fixed paraffin-embedded blocks were prepared
from the surgical resection specimens of both groups and
Hematoxylin and Eosin (H & E) stained sections were
examined. Appropriate blocks with adequate viable tumor
tissue were selected for immunohistochemical (IHC) analy-
sis. IHC was performed using commercially available mon-
oclonal antibodies for p53 (Neomarkers clone; RM-9105-
S, dilution; 1 : 200), Bcl2 (Neomarkers clone; MS-123-P1,
dilution; 1 : 150), ER (Neomarkers clone; MS-750-S, dilution;
1 : 200), PR (Neomarkers clone; MS-390-S, dilution; 1 : 100),
E-cadherin (Novocastra clone; NCL-E-CAD, dilution; 1 : 50),
Ki-67 (Neomarkers clone; RM-9105-S1, dilution; 1 : 400), and
Her-2/neu (Neomarkers clone; MS-441-S, dilution; 1 : 400).
Sections were cut from the selected blocks on poly-L-lysine
coated slides and deparaffinized and antigen retrieval was
done. Overnight incubation with primary antibody at 4∘C
was performed. Polymer based biotinylated secondary anti-
body followed by DAB (Di-amino Benzidine) visualization
and Hematoxylin counterstain were done. With each batch,
appropriate positive and negative controls (omitting the
primary antibody) were also run. IHC slides were reviewed
and semiquantitative scoring was done by two pathologists
(BK and SM). IHC finding of p53, ER, PR, Bcl2, and E-
cadherin was interpreted as 0 for no staining, 1+ for staining
in up to 30% of cells, 2+ for staining in >30 to ≤60% of
cells, and 3+ for staining in >60% of cells. For scoring
of Her-2/neu, the interpretation criterion routinely used in
carcinoma breast was applied. MIB1 Labeling Index (MIB
1 LI) was calculated by counting 500 cells in the highest
proliferating area at 400x magnification.
Survival and follow-up data was retrieved.Months of sur-
vival and outcome at the end of follow-up period were noted
by means of clinical examination, radiological evaluation,
and cytological/biopsy samples.
Statistical analysis was done using Stata 11.0 software.
Nonparametric tests (Pearson chi square and Fisher exact
test) and Kaplan-Meier analysis for period of survival were
applied.
Table 1: Comparison of expression of tissue biomarkers across US-
CT and NACT groups.
Biomarker US-CT group(%)
NACT
group (%) P value
p53 31 (62%) 29 (58%) 0.419
ER 21 (42%) 24 (48%) 0.344
PR 6 (12%) 4 (8%) 0.37
Bcl2 4 (8%) 8 (16%) 0.178
E-Cadherin 16 (32%) 13 (26%) 0.33
Her-2/neu 0 0 —
3. Results
3.1. Age and Stage Distribution. Themean age of the patients
was fifty years. Most patients were stage IIIC and only 7 cases
were stage IV (3 in NACT group, 4 in US-CT group).
3.2. Morphological Analysis. A detailed morphological anal-
ysis was done on all the tumor samples before performing
immunohistochemistry.The tumors receivingNACT showed
significantly more stromal fibrosis (Figure 1(a)) with areas
of hyalinisation, psammomatous calcification (Figure 1(b)),
inflammatory cells (Figure 1(c)), and foamy macrophages.
The residual tumor cells in post-NACT samples showed
bizarre nuclei with variable degree of cytoplasmic degener-
ative changes.
3.3. Immunohistochemical Analysis. p53 positivity was
detected in 60% of the cases (29 in NACT group, 31 in US-CT
group; Table 1; Figure 1(d)), and 75% of the positive cases had
a diffuse and widespread (2+ and 3+) staining. No difference
in the intensity of p53 positivity was found across the two
groups (Table 2). Estrogen receptor expression did not differ
significantly between the treatment groups (48% in NACT
group, 42% in US-CT group; Table 1). ER (Figure 1(e)) was
diffusely expressed (2+ and 3+) in 31% cases (𝑛 = 14 and
17, US-CT and NACT group, resp., Table 2). Progesterone
receptor (PR) was expressed in 10% cases (𝑛 = 6 and 4
in US-CT and NACT group, resp.), with only weak focal
positivity (Tables 1 and 2). 52% of the cases were both ER
and PR negative (𝑛 = 28 and 24, US-CT and NACT group,
resp., Table 3) and only 7% of the cases were both ER and
PR positive (𝑛 = 5 and 2, US-CT and NACT group, resp.,
Table 3). MIB 1 LI was significantly higher in the US-CT
group (𝑃 < 0.05, Table 4). Only 9 cases of the NACT group
showed a highMIB 1 LI which included 2 cases withMIB 1 LI
> 60% and 7 cases with MIB1 LI > 30% (Table 4). Mean MIB
1 LI was 20% and 40% in NACT (Figure 1(f)) and US-CT
groups, respectively. Bcl2 expression was observed in 12% of
the cases (8 in NACT group and 4 in US-CT group, resp.). 10
cases (𝑛 = 4 and 6, US-CT and NACT group, resp.) revealed
focal positivity (1+) and only 2 cases of NACT group showed
2+ Bcl2 positivity (Table 2). E-cadherin was focally (1+)
positive in 27% of the cases without any difference across the
treatment categories. Only 2 cases of US-CT group showed
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Table 2: Comparison of biomarkers score across the treatment groups.
Biomarker Treatment group Scoring of biomarker P (US-CT versus CT group)
0 1 2 3
p53 (𝑛 = 100) US-CT group (𝑛 = 50) 19 8 10 13 0.95
NACT group (𝑛 = 50) 21 7 8 14
ER (𝑛 = 100) US-CT group (𝑛 = 50) 29 7 8 6 0.238
NACT group (𝑛 = 50) 26 7 15 2
PR (𝑛 = 100) US-CT group (𝑛 = 50) 44 5 1 — 0.741
NACT group (𝑛 = 50) 46 4 — —
E-Cadherin (𝑛 = 100) US-CT group (𝑛 = 50) 34 14 2 — 0.495
NACT group (𝑛 = 50) 37 13 — —
Bcl2 (𝑛 = 100) US-CT group (𝑛 = 50) 46 4 — — 0.304
NACT group (𝑛 = 50) 42 6 2 —
Table 3: Comparison of expression of ER/PR.
ER/PR expression US-CT group (𝑛 = 50) NACT group (𝑛 = 50)
ER−/PR− 28 24
ER−/PR+ 1 2
ER+/PR− 16 22
ER+/PR+ 5 2
Table 4: Comparison of MIB 1 LI∗.
MIB LI∗ US-CT group(𝑛 = 50)
NACT group
(𝑛 = 50) P value
≤30% 16 (32%) 41 (82%)
0.00131–60% 29 (58%) 7 (14%)
>60% 5 (10%) 2 (4%)
∗LI: labeling index.
2+ E-cadherin positivity (Table 2). All the tumor samples
included in the study were negative for Her-2/neu.
3.4. Survival Analysis. Survival analysis was done for cases
with available follow-up data in 62 patients. Thirty patients
died during the study period, 12 inNACT group and 18 inUS-
CT group. Median overall survival of patients in the NACT
group was 32 months. For the US-CT group the median
overall survival was 29 months (Figure 2(a)).
For analyzing the correlation of survival with age, median
age (50 years) was taken for comparison. Longer median sur-
vival of 46 months was observed in patients ≤50 years of age,
in comparison to 42 months in patients >50 years of age (𝑃 =
0.34; Figure 2(b)). Prognosis was poor in patients with stage
IV disease. Survival was better in patients receiving NACT, as
compared to the patients who received conventional therapy;
however the difference was not statistically significant (𝑃 =
0.6, Figure 2(a)).
Patients with MIB 1 LI > 50% had median survival of
20.5 months with a significant poor overall survival (𝑃 <
0.001; Table 5, Figure 2(c)). Further survival analysis was
done separately in the two treatment categories taking mean
Table 5: Survival Analysis: comparison with MIB1 LI∗.
MIB 1 LI (𝑛 = 62) Death(𝑛 = 30)
Median survival
(Months) P value
MIB 1 LI ≤ 50% (𝑛 = 55) 24 46 0.001
MIB 1 LI > 50% (𝑛 = 7) 6 20.5
∗LI: labeling index.
Table 6: Survival analysis: comparison with ER expression.
ER expression (𝑛 = 62) Death(𝑁 = 30)
Median survival
(months) P value
ER positive (𝑛 = 26) 16 44 0.031
ER negative (𝑛 = 36) 14 50
MIB 1 LI for comparison. In both the treatment categories,
overall and median survival was longer in cases with a
lower MIB 1 LI (Figures 2(d) and 2(e)). Out of all the other
biomarkers analyzed, significantly poor overall survival was
seen in the cases expressing estrogen receptor (𝑃 = 0.0316;
Table 6, Figure 2(f)).
4. Discussion
Ovarian cancer is the second most common cause of
gynecological malignancy in developed countries [16, 17].
The five-year survival rate is considerably better in early
stages (around 90%) and relatively dismal (10–30%) in
advanced stage [18]. The standard protocol for management
of advanced stage SOC is upfront surgery (US) followed by
CT. In the recent years, “sandwich therapy” is being deployed
[7–9, 19] with increasing frequency worldwide. This study
was conducted to analyze the expression of tissue biomarkers
in post-NACT samples and also to correlate expression
pattern of these tissue biomarkers with survival.
4.1. Expression of Tissue Biomarkers. Study by Miller et al.
(𝑛 = 18) described no immunophenotypic difference in post-
NACT ovarian carcinomas in comparison to that of native
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Figure 1: Postneoadjuvant chemotherapy serous ovarian carcinoma showing stromal fibrosis with infiltration of eosinophils, plasma cells
(H & E stain; (a) ×100), psammomatous calcification (H & E stain; (b) ×100), and infiltration of plasma cells (H & E stain; (c) ×200).
Photomicrograph of postneoadjuvant chemotherapy serous ovarian carcinoma showing immunohistochemical expression (brown nuclear
positivity) of p53 ((d) 400x), estrogen receptor ((e) 400x), and MIB 1 ((f) 200x).
neoplasm [9]. They analyzed CK7, CA125, WT1, ER, p53,
and p16. In the current study we have analyzed seven tissue
markers in a large number of cases (𝑛 = 100). Apart from the
markers which have been evaluated earlier (p53, ER, PR, and
MIB 1), this is the first study that describes the expression of
Bcl2, E-cadherin, and Her-2/neu in post-NACT samples.
The most frequent molecular alterations in ovarian car-
cinoma are p53 mutation. Mutations, most commonly mis-
sense, are more common in advanced disease [20]. Similar
results were also observed in study done by Ferrandina and
coworkers [21]. In our study overall 60% cases were p53
positive, with no significant difference in expression pattern
between the two groups, findings similar to study done by
Miller et al. [9].
The ovarian neoplasms are characterized by changes in
their receptor status. They can either be primarily receptor
negative or may lose the receptors with disease progression
and expression varies with histological subtypes [22–25].
In this study, ER was expressed in 45% of SOCs without
any statistically significant difference across the treatment
groups. Study by Miller and coworkers showed diffuse ER
positivity in 90% cases without any difference in expression
in the postneoadjuvant tumor samples [9]. Expression of PR
observed in this study was very low, with PR being positive
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Figure 2: Kaplan-Meier survival analysis curves depicting correlation of survival outcome with treatment (a), age (b), MIB 1 LI (c), mean
MIB 1 LI in the neoadjuvant chemotherapy group (d), mean MIB 1 LI in the conventional treatment group (e), and estrogen receptor (f).
6 BioMed Research International
in only 10 cases. In contrast to the extent of ER expression,
our cases showed only focal weak expression of PR. In a study
done by Lee and his coworkers on 322 ovarian cancers, serous
subtype was mostly ER positive (77.3%), while PR was more
frequently expressed (64.2%) in endometrioid cancers [14].
Loss or altered expression of E-cadherin is responsible
for tumor dedifferentiation and invasiveness, which plays an
important role in tumor progression in epithelial tissues [26,
27]. In epithelium tumors of ovary, E-cadherin expression
is more frequently reported to occur in the cases without
metastasis [28]. E-cadherin expression was low in our series
being positive in 29 cases. No statistically significant differ-
ence was observed in expression of E-cadherin between the
two groups.
Her-2/neu has been found to have significant prognostic
and predictive value in breast cancer [29]. Its amplification
is also seen in several other tumors and has been corre-
lated with a poor prognosis. The results in ovarian cancer
regarding Her-2/neu overexpression show wide variability.
Expression of Her-2/neu in ovarian cancer ranging from
8 to 66% has been reported in various studies [30–35].
The reason is attributed to the different detection methods,
namely, immunohistochemistry (IHC), fluorescence in situ
hybridization (FISH), or chromogenic in situ hybridization
(CISH) used. Differences in the sources of tissuematerial and
tumor heterogeneity may also be responsible for the wide
variability [36, 37]. In this study Her-2/neu expression has
been analyzed by IHC with positive control slides (3+ Her-
2/neu positive carcinoma breast) being run with every batch
of IHC done on SOC. All our cases were Her-2/neu negative,
with only occasional tumor cells showing faint nonspecific
cytoplasmic staining.
The Bcl2 gene increases the survival of the cell by
inhibiting apoptosis [38]. Study done by Chan and cowork-
ers revealed that Bcl2 is expressed strongly in the surface
epithelium of normal ovaries and benign and borderline
ovarian tumors but weakly in the malignant tumors [5].
Baekelandt and coworkers demonstrated 39% positivity of
Bcl2 in ovarian cancer [39]. In this study Bcl2 positivity was
found in 12% of the cases, with 8% cases from US-CT group
and 16% fromNACT group. None of the cases showed diffuse
strong widespread reaction. No difference in the expression
pattern of Bcl2 was found between groups.
Ki-67 is a nuclear antigen used as an indicator of prolif-
eration since it is expressed during G1, S, M, and G2 periods
of cell cycle, & absent in the G0, quiescent state of the cell.
MIB 1 (Mindbomb 1) is the commonly used antibody on
formalin fixed paraffin-embedded tissues [40–42]. In our
study, a lower MIB 1 LI (<30%) was found in 82% of the
patients receiving NACT (mean MIB1LI of 20%). MIB 1 LI
was significantly higher in the patients ofUS-CT groupwhere
most of the patients had MIB 1 LI in the range of 31–60%,
with a mean of 40%. Study by Miller and coworkers revealed
a reduction inMIB 1 LI in cases displaying significant changes
in tumor morphology following NACT [9].
4.2. Effect of Treatment on Survival. As already mentioned
the standard management is upfront surgery followed by
postoperative chemotherapy. As an alternate treatment
option, some oncologists treat advanced stage cases with
NACT before the cytoreductive surgery. Meta-analysis by
Bristow (𝑛 = 835) showed a poorer outcome in patients with
NACT in comparison to primary debulking surgery [43]. A
randomized trial has been conducted with advanced stage
patients (𝑛 = 718) to compare the outcome of “sandwich
therapy” with primary debulking surgery.The study revealed
almost similar median survival in both the treatment groups,
29 months in the patients undergoing primary surgery and
30months in the NACT group [44]. Our results are similar to
this study. Various other studies have suggested that survival
of patients of advanced ovarian cancer treated with NACT
is similar to those undergoing primary surgery. However,
improvement in the performance status of the patients with
decreased operative morbidity has been observed. It has also
been observed that the number of patients attaining optimal
cytoreduction is increased with the institution of NACT [45–
48]. Further studies are required to document exact stand of
NACT in the treatment of advanced stage ovarian cancer.
4.3. Correlation of Survival with Tissue Biomarkers. Tissue
biomarkers can assist in planning treatment and also help
in predicting long-term outcome. The importance of tissue
biomarkers in predicting prognosis of ovarian cancer in
conventionally treated cases has been well documented.
However their role in predicting prognosis following NACT
has not yet been described in literature. This is the first study
exploring the significance of seven tissue biomarkers. We
found two biomarkers with statistically significant results,
MIB 1 and ER.
Higher expression of Ki 67 antigen significantly cor-
related with poor survival in our study. We found that
patients with a MIB 1 LI > 50% had poorer overall sur-
vival. Further we analysed correlation of MIB 1 LI in both
the treatment groups separately. We found significantly
poorer survival in the NACT group when MIB 1 LI was >
20%. Garzetti and coworkers found a higher level of Ki 67
antigen expression in cystadenocarcinoma, in comparison to
benign and borderline tumors. Ki 67 expression negatively
correlated with survival and a poor disease free survival was
observed in cases with higher MIB 1 LI [49]. Study by Kaern
and coworkers on advanced stage ovarian cancer patients
(𝑛 = 51) revealed overexpression ofKi-67was associatedwith
bad prognosis [50].
In our study overall survival was better in estrogen
receptor negative cases (𝑃 = 0.03). Expression of PR has been
associated with better prognosis [14]. However, no consen-
sus on prognostic significance of steroid hormone receptor
expression in ovarian tumors has been reached yet. ER and
PR expression do not significantly change with neoadjuvant
chemotherapy and their expression may vary with disease
progression along with some difference in survival. More
studies are required to conclusively determine the exact role
of these two steroidal hormones.
No statistically significant difference in survival was
found in our study between p53 negative and positive
patients in either of the groups. Many studies have shown
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that alteration of p53 (mutation/overexpression) status in
ovarian cancer does not have a consistent relationship with
response to therapy/survival [51–53]. Bartel and coworkers
demonstrated patients with normal p53 have a longer survival
time compared to patients expressing mutated p53 [54].
The absence of a clear association of p53 alterations with
patient outcomemay reflect the underlying complexities, and
mutations may represent only a subset of the functional p53
alterations.
A reduced expression of E-cadherin has been correlated
with a higher tumor grade, presence of peritoneal seeding,
and low overall survival rate [55]. Study by Dian et al. on
ovarian carcinoma samples showed significant association
of E-cadherin expression with grading and FIGO surgical
staging (FIGO I + II versus FIGO III + IV, 𝑃 = 0.020).
They found strong E-cadherin expression was less in tumors
with a higher grade [56]. They also showed that cases with
stronger E-cadherin staining intensity had better progression
free, cause-specific, and overall survival, though the data was
not statistically significant [56]. No statistically significant
difference in survival was seen with respect to E-cadherin
expression in our study.
In our study we found a longer median survival in
cases with Bcl2 positivity, in comparison to Bcl2 negative
cases. Similar trend was observed on further analysis among
the treatment groups separately. Studies on Bcl2 in relation
to prognosis are not uniform. Some studies have failed to
demonstrate any significant correlationwith survival [57].On
the other hand few studies have shown high levels of Bcl2
expression to be associated with lower chances of response to
chemotherapy and a shorter survival [58, 59]. Study done by
Kupryjan´czyk and coworkers (𝑛 = 229) revealed a negative
correlation of Bcl2 expression with survival of the patients
[59]. In contrast to these findings some studies have shown
an improved survival in patients with a high level of Bcl2
expression [39]. The expression of Bcl2 and its correlation
with survival depends on various factors including host
response, level of p 53 expression, tumor grade, and biological
behavior of the tumor.
This study analyzes the expression of tissue biomarkers in
SOCs across the conventionally treated and the neoadjuvant
chemotherapy treated group of patients. Tumor cells differ
significantly in their proliferation capacity following NACT,
indicated by a lower MIB 1 labeling index in post-NACT
samples. In the present study, MIB 1 labeling index and ER
expression inversely correlated with survival and could be
useful in predicting treatment response and prognostication.
The expression of most of the other tissue biomarkers in
serous ovarian cancer cases treated with NACT did not differ
significantly from the cases managed without preoperative
chemotherapy.However,more studies are required to validate
the role of tissue biomarkers as predictors of survival and
prognosis following NACT.
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